MedTrace Logo

Grape Polyphenols for Prevention of Chemotherapy-Induced Cardiotoxicity

NCT07419711 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-02-19

No results posted yet for this study

Summary

This pilot randomized clinical study aims to evaluate the cardioprotective effects of a grape polyphenol concentrate in patients receiving anthracycline- and/or trastuzumab-based chemotherapy. Adult patients at high or very high risk of chemotherapy-induced cardiotoxicity will be randomized to receive either a grape polyphenol concentrate or placebo for three months, starting with chemotherapy. Cardiac function and cardiotoxicity will be assessed using echocardiographic parameters and circulating biomarkers at baseline, 3 months, and 6 months.

Conditions

Interventions

DIETARY_SUPPLEMENT

Grape Polyphenol Concentrate

Grape polyphenol concentrate, 20 mg/mL; participants take 15 mL orally once daily for 3 months starting with chemotherapy.

OTHER

Placebo (Dark Grape Juice)

Placebo (dark grape juice); participants take 15 mL orally once daily for 3 months starting with chemotherapy.

Sponsors & Collaborators

  • Nazarbayev University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-09
Primary Completion
2026-05-09
Completion
2027-11-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07419711 on ClinicalTrials.gov